Oxurion NV
10.09.19
Oxurion NV to Provide Business and Clinical Update at AAO and OIS Meetings in San FranciscoSource: Oxurion NV
09.04.19
Oxurion Completes Enrollment of Phase 1 Clinical Trial Evaluating THR-687 for the Treatment of DMESource: Oxurion NV
07.01.19
Oxurion NV Reports Topline Phase 1 Results with THR-149 for the treatment of DMESource: Oxurion NV
09.10.18
Oxurion NV Announces New NYSE Euronext Brussels Stock Ticker “OXUR” and Launch of New WebsiteSource: Oxurion NV